Canopy Growth Corporation
CGCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeCanopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany,. At a $421.5M market cap, Canopy Growth Corporation ranks as a small-cap company within healthcare. The company operates through two segments, Cannabis and Storz & Bickel.
Market Cap
$421.5M
Beta
2.42
P/E (TTM)
—
P/E (Fwd)
-7.76
EPS (TTM)
$-0.63
EPS (Fwd)
$-0.12
ROE
-44.7%
ROA
-3.9%
Cash
$365.6M
Total Debt
$278.7M
Free CF
$16.1M
52W Change
-13.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $365.6M in cash comfortably exceeding the $278.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $16.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -44.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $333.3M (2023) to $284.6M (2026), a 15% decline worth watching.
With a beta above 1.5, CGC tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. No single metric tells the full story. Reviewing CGC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.